FOLD
Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. insider trading
Amicus Therapeutics, Inc. files with the SEC as a Pharmaceutical Preparations company headquartered in Princeton, NJ. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.
From SEC filings
Recent FOLD insider transactions
One insider traded FOLD on the open market on Mar 02, 2026 — 1 sale worth $322.8K, of which the one was pre-scheduled under a 10b5-1 plan.
- Bought
- —
- Sold
- $322.8K
- Net
- −$322.8K
- Insiders
- 1
1 of 1 on a 10b5-1 plan
Campbell Bradley L10b5-1
President and CEO · Director
−$322.8K
Mar 02, 2026
22,500 sh · $14.35
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Mar 02, 2026 | Campbell Bradley L10b5-1President and CEO · Director | 22,500 | $14.35 | −$322.8K |
SEC Form 4 data, Q3 2024 to Q2 2026
FOLD insider trading by quarter
Between Jul 01, 2024 and Jun 30, 2026, 4 insiders traded FOLD on the open market: 0 purchases and 22 sales worth $6M, every sale pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 13 sales ($5.4M), by 4 insiders.
| Quarter | Bought | Sold | Insiders |
|---|---|---|---|
| Q2 2026 | — | — | |
| Q1 2026 | — | −$1.4M2 sales · all on a plan | |
| Q4 2025 | — | −$4M11 sales · all on a plan | |
| Q3 2025 | — | — | |
| Q2 2025 | — | — | |
| Q1 2025 | — | −$4K1 sale · all on a plan | |
| Q4 2024 | — | −$339.4K4 sales · all on a plan | |
| Q3 2024 | — | −$240.4K4 sales · all on a plan |
- Largest sale
- −$1.1M of FOLD by Campbell Bradley L (President and CEO · Director) on Jan 20, 2026, under a 10b5-1 plan.
Open-market transactions through Jun 30, 2026most recent first
Campbell Bradley L10b5-1
President and CEO · Director
−$322.9K
Mar 02, 2026
22,500 sh · $14.35
Campbell Bradley L10b5-1
President and CEO · Director
−$1.1M
Jan 20, 2026
75,000 sh · $14.31
Clark David Michael10b5-1
Chief People Officer
−$363.3K
Dec 19, 2025
25,642 sh · $14.17
Campbell Bradley L10b5-1
President and CEO · Director
−$846.3K
Dec 15, 2025
77,926 sh · $10.86
Clark David Michael10b5-1
Chief People Officer
−$282.1K
Dec 15, 2025
25,643 sh · $11.00
Campbell Bradley L10b5-1
President and CEO · Director
−$146K
Dec 01, 2025
14,587 sh · $10.01
Rosenberg Ellen10b5-1
Chief Legal Officer
−$236.2K
Nov 26, 2025
23,621 sh · $10.00
Rosenberg Ellen10b5-1
Chief Legal Officer
−$360K
Nov 25, 2025
36,000 sh · $10.00
Castelli Jeff10b5-1
Chief Development Officer
−$773.8K
Nov 24, 2025
76,158 sh · $10.16
Rosenberg Ellen10b5-1
Chief Legal Officer
−$362.2K
Nov 24, 2025
36,000 sh · $10.06
Clark David Michael10b5-1
Chief People Officer
−$259K
Nov 24, 2025
25,643 sh · $10.10
Campbell Bradley L10b5-1
President and CEO · Director
−$146.5K
Nov 24, 2025
14,587 sh · $10.04
Clark David Michael10b5-1
Chief People Officer
−$243.9K
Nov 04, 2025
25,643 sh · $9.51
Campbell Bradley L10b5-1
President and CEO · Director
−$4K
Feb 19, 2025
400 sh · $10.00
Campbell Bradley L10b5-1
President and CEO · Director
−$75.2K
Dec 02, 2024
7,500 sh · $10.02
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Mar 02, 2026 | Campbell Bradley L10b5-1President and CEO · Director | 22,500 | $14.35 | −$322.9K |
| Jan 20, 2026 | Campbell Bradley L10b5-1President and CEO · Director | 75,000 | $14.31 | −$1.1M |
| Dec 19, 2025 | Clark David Michael10b5-1Chief People Officer | 25,642 | $14.17 | −$363.3K |
| Dec 15, 2025 | Campbell Bradley L10b5-1President and CEO · Director | 77,926 | $10.86 | −$846.3K |
| Dec 15, 2025 | Clark David Michael10b5-1Chief People Officer | 25,643 | $11.00 | −$282.1K |
| Dec 01, 2025 | Campbell Bradley L10b5-1President and CEO · Director | 14,587 | $10.01 | −$146K |
| Nov 26, 2025 | Rosenberg Ellen10b5-1Chief Legal Officer | 23,621 | $10.00 | −$236.2K |
| Nov 25, 2025 | Rosenberg Ellen10b5-1Chief Legal Officer | 36,000 | $10.00 | −$360K |
| Nov 24, 2025 | Castelli Jeff10b5-1Chief Development Officer | 76,158 | $10.16 | −$773.8K |
| Nov 24, 2025 | Rosenberg Ellen10b5-1Chief Legal Officer | 36,000 | $10.06 | −$362.2K |
| Nov 24, 2025 | Clark David Michael10b5-1Chief People Officer | 25,643 | $10.10 | −$259K |
| Nov 24, 2025 | Campbell Bradley L10b5-1President and CEO · Director | 14,587 | $10.04 | −$146.5K |
| Nov 04, 2025 | Clark David Michael10b5-1Chief People Officer | 25,643 | $9.51 | −$243.9K |
| Feb 19, 2025 | Campbell Bradley L10b5-1President and CEO · Director | 400 | $10.00 | −$4K |
| Dec 02, 2024 | Campbell Bradley L10b5-1President and CEO · Director | 7,500 | $10.02 | −$75.2K |
From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.
Amicus Therapeutics, Inc. company record
- SEC industry classification
- Pharmaceutical Preparations
- Headquarters
- Princeton, NJ
- Incorporated in
- DE
- SEC Central Index Key
- 0001178879
Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.
After insiders bought FOLD
What the stock actually did in the 90 days following each open-market purchase
Don't check FOLD — let it ping you
Get told the moment an insider moves on FOLD
Pro watches Amicus Therapeutics, Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add FOLD to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.
The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.
How to read FOLD insider activity
- Open-market purchase (code P)
- An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
- Grants and option exercises (codes A, M)
- Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
- Cluster buy
- Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.
Other Health Care tickers
Questions
- Are FOLD insiders buying or selling?
- Between Mar 02, 2026 and Mar 02, 2026, 1 Amicus Therapeutics, Inc. insider made no open-market purchases and 1 sale worth $322.8K, a net sale of $322.8K. 1 of the sales was pre-scheduled under a Rule 10b5-1 plan.
- How much FOLD stock have insiders bought and sold in the last two years?
- Between Jul 01, 2024 and Jun 30, 2026, 4 Amicus Therapeutics, Inc. insiders made no open-market purchases and 22 sales worth $6M. Every one of the sales was pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 13 sales ($5.4M). The largest sale was Campbell Bradley L selling $1.1M on Jan 20, 2026.
- What was the largest recent FOLD insider trade?
- Campbell Bradley L (President and CEO · Director) sold $322.8K of FOLD stock on Mar 02, 2026 at about $14.35 a share, under a pre-scheduled 10b5-1 plan.
- When did an insider last buy FOLD shares?
- No open-market purchase by a Amicus Therapeutics, Inc. insider appears in the filings from Mar 02, 2026 to Mar 02, 2026 — every recorded open-market transaction in that period was a sale.
- Where does FOLD insider trading data come from?
- From the Form 4 filings Amicus Therapeutics, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.
Get the free Insider Brief
Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.